WO2003025135A3 - Genes associated with malignant neoplasms - Google Patents

Genes associated with malignant neoplasms Download PDF

Info

Publication number
WO2003025135A3
WO2003025135A3 PCT/US2002/029371 US0229371W WO03025135A3 WO 2003025135 A3 WO2003025135 A3 WO 2003025135A3 US 0229371 W US0229371 W US 0229371W WO 03025135 A3 WO03025135 A3 WO 03025135A3
Authority
WO
WIPO (PCT)
Prior art keywords
malignant neoplasms
neoplasms
genes associated
omentum
vulva
Prior art date
Application number
PCT/US2002/029371
Other languages
French (fr)
Other versions
WO2003025135A2 (en
Inventor
Michele Nation
James C Diggans
Mark Porter
Sun Lu
Michael Orr
Original Assignee
Gene Logic Inc
Michele Nation
James C Diggans
Mark Porter
Sun Lu
Michael Orr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Logic Inc, Michele Nation, James C Diggans, Mark Porter, Sun Lu, Michael Orr filed Critical Gene Logic Inc
Priority to AU2002362309A priority Critical patent/AU2002362309A1/en
Publication of WO2003025135A2 publication Critical patent/WO2003025135A2/en
Publication of WO2003025135A3 publication Critical patent/WO2003025135A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates generally to the changes in gene expression in malignant neoplasms. The invention relates specifically to human genes which correspond to mRNA species that are differentially expressed in malignant neoplasms compared to normal tissues, such as neoplasms of the cervix, endometrium, uterus, breast, colon, rectum, intestine, kidney, liver, lung, stomach, ovary, pancreas, thyroid gland, lymph node, omentum, skin, esophagus, larynx, adrenal gland, prostate, vulva, connective tissue or soft tissue.
PCT/US2002/029371 2001-09-14 2002-09-16 Genes associated with malignant neoplasms WO2003025135A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002362309A AU2002362309A1 (en) 2001-09-14 2002-09-16 Genes associated with malignant neoplasms

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
US31890501P 2001-09-14 2001-09-14
US31889101P 2001-09-14 2001-09-14
US60/318,891 2001-09-14
US60/318,905 2001-09-14
US32246801P 2001-09-17 2001-09-17
US60/322,468 2001-09-17
US32279001P 2001-09-18 2001-09-18
US32273201P 2001-09-18 2001-09-18
US32273301P 2001-09-18 2001-09-18
US60/322,733 2001-09-18
US60/322,732 2001-09-18
US60/322,790 2001-09-18
US32307801P 2001-09-19 2001-09-19
US60/323,078 2001-09-19
US32424601P 2001-09-24 2001-09-24
US32405001P 2001-09-24 2001-09-24
US60/324,050 2001-09-24
US60/324,246 2001-09-24
US32462101P 2001-09-26 2001-09-26
US60/324,621 2001-09-26
US32491001P 2001-09-27 2001-09-27
US60/324,910 2001-09-27
US37359502P 2002-04-19 2002-04-19
US60/373,595 2002-04-19

Publications (2)

Publication Number Publication Date
WO2003025135A2 WO2003025135A2 (en) 2003-03-27
WO2003025135A3 true WO2003025135A3 (en) 2003-10-23

Family

ID=27583838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/029371 WO2003025135A2 (en) 2001-09-14 2002-09-16 Genes associated with malignant neoplasms

Country Status (2)

Country Link
AU (1) AU2002362309A1 (en)
WO (1) WO2003025135A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
WO2005100608A2 (en) 2004-04-09 2005-10-27 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Diagnostic tool for diagnosing benign versus malignant thyroid lesions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054963A2 (en) * 1997-06-06 1998-12-10 Human Genome Sciences, Inc. 207 human secreted proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054963A2 (en) * 1997-06-06 1998-12-10 Human Genome Sciences, Inc. 207 human secreted proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 15 September 2000 (2000-09-15), XP002965806, Database accession no. (BE745101) *
DATABASE GENBANK [online] XP002965804, Database accession no. (AAV84508) *
DATABASE GENBANK [online] XP002965805, Database accession no. (AAV84627) *

Also Published As

Publication number Publication date
AU2002362309A1 (en) 2003-04-01
WO2003025135A2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
ATE478952T1 (en) 36P6D5: SECRETED TUMOR PROTEIN
WO2004050026A3 (en) Compositions and methods for treating prostate cancer
DK1556058T3 (en) Pharmaceutical compositions comprising oestetrol derivatives for use in cancer therapy
WO2003072125A8 (en) Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
MXPA02011093A (en) Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers.
MXPA05008319A (en) Oligomeric compounds for the modulation of survivin expression.
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
WO2004069992A3 (en) Oligomeric compounds for the modulation of ras expression
ATE413180T1 (en) METHYLATION-MODULATING COMPOUNDS FOR THE INTRADUCTAL TREATMENT OF BREAST CANCER
WO2006027693A8 (en) Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
ZA200900224B (en) Gene Family (LBFL313) associated with pancreatic cancer
HK1116186A1 (en) Azaxanthones and use thereof for treating tumors
WO2005065361A3 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
WO2003025135A3 (en) Genes associated with malignant neoplasms
ATE373711T1 (en) TISSUE-SPECIFIC PROTEIN 103P2D6, HIGHLY EXPRESSED IN VARIOUS TYPES OF CANCER
WO2001059110A3 (en) 34p3d7: a tissue specific protein highly expressed in prostate cancer
WO2001098456A3 (en) IDENTIFICATION OF cDNAs ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
WO2001051515A3 (en) Genes differentially expressed in breast cancer
WO2004078123A3 (en) Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use
WO2005048956A3 (en) Estradiol-related compounds and methods of use as anti-tumor agents
WO2003042700A3 (en) Breast cancer associated polypeptide
MXPA02001238A (en) Hydralazine and procanaimide use in cancer treatment as reactivators of the expression of tumor suppressor genes.
UA49216A (en) Remedy for treating complication following resection of malignant tumors of skin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP